Form 8-K - Current report:
SEC Accession No. 0001193125-25-127595
Filing Date
2025-05-27
Accepted
2025-05-27 16:30:26
Documents
12
Period of Report
2025-05-22
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d82533d8k.htm   iXBRL 8-K 31445
  Complete submission text file 0001193125-25-127595.txt   149674

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA antx-20250522.xsd EX-101.SCH 2875
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20250522_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20250522_pre.xml EX-101.PRE 11724
14 EXTRACTED XBRL INSTANCE DOCUMENT d82533d8k_htm.xml XML 3759
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 25989026
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)